Shopping Cart
- Remove All
- Your shopping cart is currently empty
PF-4942847, a novel oral Hsp90 inhibitor, has emerged as a candidate compound for clinical development in TNBC by synergistically targeting multiple signaling pathways. Furthermore, the degradation of AKT in PBLs may serve as a biomarker in clinical development.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | PF-4942847, a novel oral Hsp90 inhibitor, has emerged as a candidate compound for clinical development in TNBC by synergistically targeting multiple signaling pathways. Furthermore, the degradation of AKT in PBLs may serve as a biomarker in clinical development. |
Alias | PF4942847, PF04942847, PF 4942847 |
Molecular Weight | 516.3 |
Formula | C20H18Cl2F3N7O2 |
Cas No. | 1046859-34-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.